All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Abemaciclib Plus Aromatase Inhibitor Generates Survival Benefit in HR+/HER2- Breast Cancer

September 9th 2022

The addition of abemaciclib to a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer.

Preoperative Nivolumab Alone or With Relatlimab Allows for Surgical Feasibility in Resectable NSCLC

September 9th 2022

Preoperative nivolumab with or without relatlimab increased surgical feasibility in patients with resectable non–small cell lung cancer.

Higher-Dose Rhenium-186 Nanoliposome Demonstrates OS Advantage in Recurrent Glioma

September 9th 2022

Rhenium-186 nanoliposome administered at doses exceeding 100 Gy demonstrated promising safety and efficacy results in patients with recurrent glioma.

Olaparib Maintenance Provides Sustained OS Benefit in Newly Diagnosed, BRCA-Mutated, Advanced Ovarian Cancer

September 9th 2022

Two years of olaparib maintenance therapy elicited a long-term overall survival benefit vs placebo in patients with newly diagnosed advanced ovarian cancer harboring a BRCA mutation.

Olaparib Plus Bevacizumab Maintenance Therapy Provides OS Benefit in Advanced HRD-Positive Ovarian Cancer

September 9th 2022

Maintenance olaparib plus bevacizumab following first-line standard-of-care treatment improved overall survival in patients with newly diagnosed advanced ovarian cancer, particularly those with homologous recombination deficiency.

Rucaparib Demonstrates Survival Benefits in BRCA1/2-Mutated, Relapsed Ovarian Cancer.

September 9th 2022

Rucaparib elicited a progression-free survival benefit and comparable overall survival (OS) vs chemotherapy in patients with BRCA1/2-mutated, relapsed ovarian cancer who were sensitive to platinum-based chemotherapy.

Mount Sinai Researchers Report Encouraging Immunotherapy Option for Relapsed Myeloma

September 9th 2022

T-cell redirection therapy has shown to be effective in patients unresponsive to initial bispecific antibody treatment.

Hodgkin Lymphoma Pioneer Saul A. Rosenberg, MD, FASCO, Dies at 95

September 8th 2022

Saul A. Rosenberg, MD, FASCO, the Maureen Lyles D’Ambrogio Professor Emeritus at Stanford School of Medicine and the 2019 Giants of Cancer Care® award winner for Lymphoma, died at the age of 95.

Azacitidine/Venetoclax Combo Delivers Promising Early Results in High-Risk CML, MDS

September 8th 2022

Azacitidine plus venetoclax showed encouraging activity in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

Pembrolizumab/Anlotinib Combo Has Efficacy in Refractory or Platinum-Resistant Recurrent High-Grade Serous Ovarian Cancer

September 8th 2022

Pembrolizumab monotherapy and in combination with anlotinib demonstrated encouraging efficacy and safety when administered to patients with refractory or platinum-resistant recurrent high-grade serous ovarian cancer.

European Commission Grants Orphan Drug Designation to Nana-val for Peripheral T-cell Lymphoma

September 8th 2022

The European Commission has granted an orphan drug designation to nanatinostat and valganciclovir for use as a potential therapeutic option in patients with peripheral T-cell lymphoma.

IU School of Medicine Names First Walther Scholar in Psycho-Oncology

September 8th 2022

Indiana University School of Medicine has named Shelley Johns, PsyD, ABPP, the Walther Scholar in Psycho-Oncology.

AVA6000 Granted FDA Orphan Drug Status for Soft Tissue Sarcoma

September 8th 2022

The FDA has granted an orphan drug designation to AVA6000, a modified form of doxorubicin, for the treatment of patients with soft tissue sarcoma.

AI-Powered Focal Therapy Maps Future Treatment Paradigm in Prostate Cancer

September 8th 2022

For clinicians tasked with treating patients with prostate cancer, disease visualization has traditionally consisted of imprecise techniques such as MRI. However, a new artificial intelligence-based approach by Avenda Health is poised to potentially revolutionize the treatment landscape in the field.

FDA Grants Orphan Drug Designation to WP1122 for Glioblastoma Multiforme

September 8th 2022

The FDA has granted an orphan drug designation to WP1122 as a potential therapeutic option for patients with glioblastoma multiforme.

FDA Grants Fast Track Designation to AMB-05X in Tenosynovial Giant Cell Tumors

September 7th 2022

The FDA has granted fast track designation to AMB-05X for the treatment of patients with tenosynovial giant cell tumors.

Toripalimab Plus Concurrent Chemoradiation Produces Activity in Locally Advanced Cervical Cancer

September 7th 2022

Toripalimab and concurrent chemoradiation elicited encouraging activity with acceptable tolerability in patients with locally advanced cervical cancer.

Magrolimab Plus Azacitidine May Be a Potential Treatment Option in High-Risk MDS

September 7th 2022

Naval G. Daver, MD, discusses the rationale for the ongoing ENHANCE trial and explained magrolimab’s unique role as a macrophage immune checkpoint blocker. He also outlines unmet needs throughout the entire high-risk myelodysplastic syndrome population, and how novel approaches, such as magrolimab combinations, may fulfill these needs.

Emavusertib Is Active in Heavily Pretreated AML and High-Risk MDS With Targeted Mutations

September 7th 2022

Emavusertib elicited antitumor activity when given as a monotherapy in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome that harbored a spliceosome or FLT3 mutation.

Sylvester Expert Co-Authors Guidelines for Optimizing Cancer Survivor Nutrition and Physical Activity

September 7th 2022

More scientific evidence about the importance of nutrition and physical activity for cancer survivors has emerged in the past 10 years, prompting the American Cancer Society to update its guidance for physicians and patients.